Physician profile
Travis Massengill
NPI 1740693696
$7,281.48
in general payments reported to CMS, 2019-2025
21 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $39.63 · 2021: $586 · 2022: $444 · 2023: $3,341 · 2024: $2,294 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,210 · Travel and Lodging: $2,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,210.21 |
| Travel and Lodging | $2,900.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,604.14 | 2023-2024 | Micra |
| Abbott Laboratories | $954.02 | 2022-2024 | Aveir, Mitraclip |
| Boston Scientific Corporation | $575.59 | 2019-2024 | Watchman Flx, Watchman, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $559.18 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $535.40 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $294.10 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Atricure, INC. | $125.82 | 2023 | |
| Cvrx, INC. | $98.44 | 2025 | Barostim Neo System |
| Pfizer INC. | $87.50 | 2021-2025 | |
| Ge Healthcare | $85.77 | 2023 | Giraffe Omnibed Carestation |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.75 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.01 | 2019 | |
| Inspire Medical Systems, INC. | $39.42 | 2024 | Inspire |
| Abiomed | $39.31 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $30.86 | 2022-2023 | Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $24.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.75 | 2020-2021 | |
| Innovation Technologies INC | $22.18 | 2024 | Irrisept |
| Scpharmaceuticals INC. | $18.92 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $13.83 | 2025 | Uptravi |
| Merck Sharp & Dohme LLC | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Massengill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.